Chemopreventive Agent Development

Designs, develops, implements, and monitors research on interventions that may block, reverse, or delay the early stages of cancer. Investigates nutrients, micronutrients, natural products, pharmacologic agents, biomolecules, and vaccines from preclinical to early-phase I clinical studies. Helps investigators to bridge the gaps between biology and identifying potential targets, and between discovery of targets and agents and clinical testing in people.

Major Programs

Staff List

Grid View

Name, Email, Phone	Room	Group(s)/Office
Asefa, Wosene wosene.asefa@nih.gov 240-276-6422	5E504	Program Support Assistant \| Chemopreventive Agent Development
Biswas, Kajal, Ph.D. kajal.biswas2@nih.gov 240-276-5614	5E540	Program Officer \| Chemopreventive Agent Development
Cholewa, Brian, Ph.D. brian.cholewa@nih.gov 240-276-7545	5E446	Deputy Chief \| Chemopreventive Agent Development
Clifford, John, Ph.D. john.clifford@nih.gov 202-235-4482	5E430	Program Officer \| Chemopreventive Agent Development
Gunasekharan, Vignesh, Ph.D. vignesh.gunasekharan@nih.gov 240-276-5814	5E438	Program Officer \| Chemopreventive Agent Development
Mohammed, Altaf, Ph.D. altaf.mohammed@nih.gov 240-276-6082	5E542	Deputy Chief \| Chemopreventive Agent Development
Nalli, Ancy, Ph.D., M.S. ancy.nalli@nih.gov 202-276-5265	5E536	Program Officer \| Chemopreventive Agent Development
Sei, Shizuko, M.D. shizuko.sei@nih.gov 240-276-5005	5E452	Co-Chief \| Chemopreventive Agent Development
Shoemaker, Robert, Ph.D. robert.shoemaker@nih.gov 240-276-7077	5E454	Co-Chief \| Chemopreventive Agent Development Acting Chief \| Nutritional Science
Vlad, Anda, M.D., Ph.D. anda.vlad@nih.gov 240-276-6422	5E538	Program Officer \| Chemopreventive Agent Development

Grants

PI Name Sort descending	PI Organization	Title	Grant Number	Program Official
Siminski, Suzanne M.	Frontier Sci & Technology Rsch Fdn, Inc United States	CASCADE Coordinating Center	5U24CA275417-04	Maria Silvina Frech, Ph.D., M.S.
Singal, Amit	Ut Southwestern Medical Center United States	Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules	4U01CA283935-03	Sidney Fu, M.D.
Singal, Amit	Ut Southwestern Medical Center United States	Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States	5U01CA230694-05
Singal, Amit	Ut Southwestern Medical Center United States	Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis	5R01CA222900-06
Singal, Amit	Ut Southwestern Medical Center United States	Clinical Validation Center for Hepatocellular Carcinoma	5U01CA271887-04	Indu Kohaar, Ph.D., M.Phil., M.Sc.
Siskind, Leah J	University Of Louisville United States	Protecting the kidney from cisplatin induced injury and progression to chronic kidney disease	1R01CA305985-01	Marjorie Perloff, M.D.
Skates, Steven J	Massachusetts General Hospital United States	Genome-wide methylation and proteomic analysis of uterine lavage and cervical swab for early detection of ovarian cancer	5U2CCA271871-03	Christos Patriotis, Ph.D., M.Sc.
Skates, Steven J	Massachusetts General Hospital United States	Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls	5U01CA260758-05	Claire Zhu, Ph.D.
Skubitz, Amy Patrice	University Of Minnesota United States	A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection	5R01CA262153-05	Christos Patriotis, Ph.D., M.Sc.
Slager, Susan L	Mayo Clinic Rochester United States	The genetic and epigenetic etiology of progression from the precursor state to chronic lymphocytic leukemia (CLL)	4R01CA258465-04	Nicholas Hodges, Ph.D.
Smith, Ellen Mary Lavoie	University Of Alabama At Birmingham United States	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study	5R01CA235726-07	Brennan Streck, Ph.D., RN, M.P.H.
Smith, Jennifer Susan	Univ Of North Carolina Chapel Hill United States	UNC CASCADE Network Research Base	5UG1CA275403-04	Maria Silvina Frech, Ph.D., M.S.
Sohl, Stephanie Jean	Wake Forest University Health Sciences United States	REmotely-delivered Supportive Programs for Improving surgical pain and disTrEss (RESPITE)	5R01CA266995-04	Goli Samimi, Ph.D., M.P.H.
Somers, Tamara J	Duke University United States	A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial	5R01CA237892-05	Brennan Streck, Ph.D., RN, M.P.H.
Song, Ming	University Of Louisville United States	Dietary fructose and NASH/HCC progression	5R21CA290420-02	Amit Kumar, Ph.D.

Chemopreventive Agent Development

On This Page

Major Programs

Staff List

Grants